Months 0–3
Recruit scientific leadership. Authenticate material. Lock functional, molecular, and safety thresholds.
AntaeusBiosciencesOne-page deck ↗
Investors
Fund a decision.
Earn the next stage.
Antaeus Biosciences is raising $1–2M pre-seed. Bemitil is the lead molecule. The first functional question is whether it preserves work capacity under heat. The program is preclinical. Human efficacy is unproven.
The round
- Target
- $1–2M pre-seed
- Instrument
- [TERMS: fill in]
- Valuation or cap
- [VALUATION OR CAP: fill in]
- Minimum check
- [MINIMUM CHECK: fill in]
- Committed capital
- [COMMITTED CAPITAL: fill in]
Terms and commitments will be stated here once confirmed.
What $1.5M buys
This is an illustrative 18-month allocation. It is a planning budget, not a set of contracted quotes.
| Workstream | Share | Amount |
|---|---|---|
| Functional pharmacology / PK | 25% | $375,000 |
| Molecular profiling | 20% | $300,000 |
| Authenticated material and formulation | 15% | $225,000 |
| Initial safety | 10% | $150,000 |
| Scientific leadership and personnel | 15% | $225,000 |
| AI and evidence data | 5% | $75,000 |
| IP and regulatory | 5% | $75,000 |
| Operations and contingency | 5% | $75,000 |
| Total | 100% | $1,500,000 |
Capital follows the gates
Months 3–9
Run molecular profiling and functional heat testing. Seek independent confirmation.
Month nine
Stop candidate advancement for failed replication or unacceptable safety.
The 18-month allocation is a planning horizon. The month-nine gate determines whether candidate advancement continues. A gene-expression signal alone does not establish a useful medicine.
What exists. What must be built.
Founder Gregory Battenfield built Molekul.io, an AI-assisted research archive of 90+ compounds and 400+ source records. These are founder-reported minimums, not independently verified.
No scientific lead is hired. No lab is contracted. No US API production or government partnership is secured.
Request the data room
Tell the founder who you are and what you want to review. Access is handled by the founder.
investors@antaeusbiosciences.com
Book a conversation
[BOOKING URL: fill in]
Until a booking link is supplied, email the founder to arrange a conversation.